Rift Valley Fever – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Rift Valley Fever – Drugs In Development, 2024 report and make more profitable business decisions.
Rift Valley fever (RVF) is a zoonotic viral disease that primarily affects animals but can also affect humans. Contact with blood, body fluids, or tissues of the infected animals can cause RVF. Currently, no human-to-human transmission of RVF virus has been documented. RVF virus has an incubation period of 2-6 days after exposure. Symptoms include fever, weakness, back pain, and dizziness. If early symptoms do not appear, then RVF virus can cause 3 distinct syndromes: ocular disease, meningoencephalitis, or hemorrhagic fever. RVF virus infections can only be diagnosed with RT-PCR, ELISA, and virus isolation cell culture. There is no FDA approved drug to treat RVF as most of the cases are mild and self-limiting. It can be prevented by a sustained animal vaccination program.
The Rift Valley Fever drugs in development market research report provide comprehensive information on the therapeutics under development for Rift Valley Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rift Valley Fever and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Rift Valley Fever | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 7 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Rift Valley Fever therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Rift Valley Fever pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Rift Valley Fever treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
BunyaVax BVDefender Pharmaceuticals Inc
Eirium AB
Moderna Inc
Theravectys SA
University of Oxford
Vanderbilt University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Rift Valley Fever reports